10 maj: Indre værdi af SmallCap Danmark A/S er opgjort til 10,6 kr. pr. a..
10 maj: Danske Bank udnævner ny administrerende direktør
10-05-2019 08:10:22

Ambu A/S: Ambu appoints new CEO

Ambu’s board of directors has appointed Juan-José Gonzalez as the new CEO, effective May 15, 2019, to replace Lars Marcher who resigns from his position.

Jens Bager, Chairman of the Ambu Board of Directors, comments, “During Lars Marchers' leadership, Ambu has developed a strong and broad platform of medtech products, which have formed the basis for impressive growth. I and the rest of the board would like to thank Lars very much for his contribution to this remarkable decade in Ambu’s history. At the same time, I am pleased to have secured Juan-José Gonzalez, whom I am confident will be an excellent successor and the right choice to lead Ambu into its next growth phase.

Juan-José Gonzalez is an engineer and MBA graduate and has held a number of senior positions in the US healthcare group Johnson & Johnson for the past 12 years. Most recently, he has been President for the activities of the subsidiary DePuy Synthes in the US, with a turnover of DKK 33bn and more than 5,000 employees. DePuy Synthes is one of the world's leading manufacturers of orthopedic and neurosurgical products. Prior to joining Johnson & Johnson in 2007, Juan-José Gonzalez was a commercial director of the pharmaceutical company Pfizer, responsible for Europe, Africa and the Middle East, and for five years employed by the global consulting firm McKinsey & Company. Juan-José Gonzalez is 46 years old, an American citizen and relocates from the United States to Denmark with his wife and their two children.

"Ambu is facing a major international breakthrough with a number of high-tech products in the business area of Visualization with a broad program of single-use endoscopes in the USA and the rest of the world. With Juan-José Gonzalez as CEO, we ensure that Ambu also has the necessary global experience to execute the announced strategy and ensure the succesful commercialization of our product launches,” says Jens Bager.

Juan-José Gonzalez looks forward to joining Ambu as the new CEO. “The strength of Ambu is the company’s ability to deliver on differentiated innovation. Its pioneering of single-use endoscopy is a great example of Ambu’s focus on innovation. I am deeply committed to the plan to continue Ambu’s legacy of bringing innovative products to patients around the world. With Ambu’s recent launches, strong pipeline and committed people, I am very confident about our future." says Juan-José Gonzalez.

Financial expectations

The replacement of the CEO does not change the announced financial expectations for 2018/19 – except for the one-off costs listed below – or the financial targets for 2020 as outlined in the Big Five strategy. Planned product launches up to the end of the financial year 2019/20 and Ambu´s program for the upcomming DDW congress in San Diego on 18-21 May 2019 is thus unaffected by this.

In relation to Lars Marcher's resignation, there will be one-off costs of approx. DKK 38m, which for accounting purposes will be recognized in the income statement as Special items. The costs relates, among other things, to salary during the period of notice and the costs of the remaining value of already granted share options calculated according to the Black Scholes formula. These Black Scholes costs amounts to DKK 16m which so far has been distributed over the allocation period of the share options, but will now be fully charged to the income statement in the 3rd quarter of the financial year 2018/19 as a direct consequence of Lars Marcher's resignation.Before special items as referred above the financial expectations for the financial year 2018/19 are unchanged compared to the guidance provided in the interim report for our 2nd quarter on May 1, 2019, and can hereafter be summarized as:

  • Organic growth of approx. 15-16%.
  • EBIT margin before special items of approx. 22-24%.
  • Free cash flow of approx. DKK 400-475m.

Contact

For further information please contact:

Jens Bager, Chairman of the Board, tel. +45 2299 0304

Michael Højgaard, CFO, tel. +45 4030 4349

Press Inquiries: Morten Huse Eikrem-Jeppesen, PressConnect, tel. +45 5385 0770

Attachment

logo.png

Relateret indhold
16 aug - 
Fredagens aktier: Gode Carlsberg-takter hjalp Unibrew o..
09 aug - 
Aktier/åbning: Novo til tops i C25 - Veloxis og H+H til..
09 aug - 
Aktier/tendens: Novo i fokus i uændret til let positivt..
Relateret debat
16 aug - 
Det er vist lidt af en højdespringer i dag:) Når der er..
12 aug - 
Læs Børsen idag om Ambu. Taastrup
11 aug - 
Fuldstændig enig i dine betragtninger Sølvfisken!
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Aktionærer kræver milliarder i erstatning fra Novo Nordisk

16-08-2019 14:38:08
Medicinalvirksomheden Novo Nordisk er blevet sagsøgt af en gruppe aktionærer for at have givet vildledende information til aktiemarkedet.De kræver en samlet erstatning på 11,8 mia. kr. for tab på deres aktier. Det skriver Børsen, hvilket bekræftes af Novo Nordisk i en meddelelse til fondsbørsen.- Novo Nordisk er uenig i anklagerne og er klar til at forsvare selskabet i denne sag, lyder det i medde..

Maersk Drilling får forlænget kontrakt på boreskib i Ækvatorialguinea

16-08-2019 11:03:22
Maersk Drilling har forlænget opholdet for boreskibet Maersk Voyager, der skal bore ude for Ækvatorialguineas kyst.Selskabet har igennem Kosmos Energy forlænget en borekontrakt, der tidligere var indgået med Noble Energy. Det skriver selskabet på Twitter.Originalt skulle Maersk Drilling bore en enkelt brønd for selskabet Noble Energy, og den aftale indeholdt en option på endnu en boring. Den optio..

Aktier/tendens: Fokus på torsdagens regnskaber i positivt marked

16-08-2019 08:19:10
Der er udsigt til en positiv slutning på aktieugen, der han været karakteriseret ved en sværm af regnskaber fra flere C25-selskaber.Futures på de amerikanske aktieindeks stiger 0,7 pct. og det samme er tilfældet for DAX-futuren. De asiatiske aktier ligger også overvejende højere fredag morgen.Torsdagens regnskaber kan påvirke igen fredag, når analytikerne smider regnskaberne i regnearkene og komme..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Fredagens aktier: Gode Carlsberg-takter hjalp Unibrew op på grøn dag
2
USA/strateger: Frygten for recession er overdrevet
3
Coloplast: Direktionsmedlem udnytter optioner og scorer milliongevinst
4
Tivoli/CFO: Vores high end-forretning fungerer rigtig godt

Relaterede aktiekurser

Ambu A/S 105,60 6,1% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
17. august 2019 14:45:23
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190809.4 - EUROWEB6 - 2019-08-17 14:45:23 - 2019-08-17 14:45:23 - 1 - Website: OKAY